At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Netarsudil Ophthalmic Solution 0.02% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure
In Brief
A Phase 2 clinical trial evaluating Netarsudil Ophthalmic Solution 0.02% and Placebo Comparator for Primary Open Angle Glaucoma or Ocular Hypertension. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartOct 2017
Primary CompletionApr 2018
TodayJul 2026
First PostedJul 28, 2017
Enrollment StartOct 20, 2017
Primary CompletionApr 19, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.9 years ago
Interventions
Netarsudil Ophthalmic Solution 0.02%drug
1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
Placebo Comparatorother
1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye